| Natural variation in the parameters of innate immune cells is preferentially driven by genetic factors E Patin, M Hasan, J Bergstedt, V Rouilly, V Libri, A Urrutia, C Alanio, ... Nature immunology 19 (3), 302-314, 2018 | 260 | 2018 |
| Human genetic variants and age are the strongest predictors of humoral immune responses to common pathogens and vaccines P Scepanovic, C Alanio, C Hammer, F Hodel, J Bergstedt, E Patin, ... Genome medicine 10, 1-13, 2018 | 139 | 2018 |
| A comprehensive assessment of demographic, environmental, and host genetic associations with gut microbiome diversity in healthy individuals P Scepanovic, F Hodel, S Mondot, V Partula, A Byrd, C Hammer, C Alanio, ... Microbiome 7 (1), 130, 2019 | 129* | 2019 |
| The SIB Swiss Institute of Bioinformatics’ resources: focus on curated databases SIB Swiss Institute of Bioinformatics Members Nucleic acids research 44 (D1), D27-D37, 2016 | 51 | 2016 |
| Integrative analysis of the plasma proteome and polygenic risk of cardiometabolic diseases SC Ritchie, SA Lambert, M Arnold, SM Teo, S Lim, P Scepanovic, ... Nature metabolism 3 (11), 1476-1483, 2021 | 50 | 2021 |
| Human genomics of the humoral immune response against polyomaviruses F Hodel, AY Chong, P Scepanovic, ZM Xu, O Naret, CW Thorball, ... Virus evolution 7 (2), veab058, 2021 | 13 | 2021 |
| Human genomics of acute liver failure due to hepatitis B virus infection: An exome sequencing study in liver transplant recipients S Asgari, N Chaturvedi, P Scepanovic, C Hammer, N Semmo, E Giostra, ... Journal of viral hepatitis 26 (2), 271-277, 2019 | 6 | 2019 |
| Hepatocyte Growth Factor-mediated satellite cells niche perturbation promotes development of distinct sarcoma subtypes D Morena, N Maestro, F Bersani, PE Forni, MF Lingua, V Foglizzo, ... Elife 5, e12116, 2016 | 5 | 2016 |
| P805 Selnoflast, a potent NLRP3 inhibitor-results from a phase 1b experimental medicine study in patients with Ulcerative Colitis B Klughammer, L Piali, AC Nica, S Nagel, L Bailey, C Jochum, ... Journal of Crohn's and Colitis 17 (Supplement_1), i938-i938, 2023 | 3 | 2023 |
| A randomized, double-blind phase 1b study evaluating the safety, tolerability, pharmacokinetics and pharmacodynamics of the NLRP3 inhibitor selnoflast in patients with moderate … B Klughammer, L Piali, A Nica, S Nagel, L Bailey, C Jochum, S Ignatenko, ... Clinical and Translational Medicine 13 (11), e1471, 2023 | 2 | 2023 |
| Gut Microbiota Is Associated with Onset and Severity of Type 1 Diabetes in Nonobese Diabetic Mice Treated with Anti–PD-1 S Patel, E Becker, C Ploix, G Steiner, P Scepanovic, M Fueth, ... ImmunoHorizons 7 (12), 872-885, 2023 | | 2023 |
| Genetic determinants of healthy human immune variance: from humoral response to microbiome diversity P Scepanovic EPFL, 2018 | | 2018 |
Christian HammerAltos LabsVerified email at altoslabs.com
